Skip to main content
Premium Trial:

Request an Annual Quote

Cogenics, Epigenomics Pen Co-Marketing Pact

NEW YORK (GenomeWeb News) — Cogenics and Epigenomics have signed a co-marketing agreement for DNA methylation, Cogenics’ parent company Clinical Data said today.
Under the deal, Cogenics will promote Epigenomics' services for genome-wide DNA methylation analysis, bisulfite sequencing, and PCR, which are performed in Epigenomics’ facilities in Germany.
Also under the deal, the companies will offer regulated DNA methylation analyses in Cogenics’ US labs. Epigenomics will promote these services through its Clinical Solutions segment.  
Robert Bondaryk, senior vice president and general manager of Cogenics, said the pact expands the company’s biomarker offerings to include DNA methylation for disease diagnosis, prognosis, and drug response prediction.
Christina Dahlstroem, Clinical Solutions’ senior vice president, said the agreement will be “particularly important” to her company when pharmaceutical customers begin to use these biomarkers in clinical trials.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.